Walsh T J, Auger F, Tatem B A, Hansen S L, Standiford H C
J Antimicrob Chemother. 1986 Jan;17(1):75-82. doi: 10.1093/jac/17.1.75.
Novobiocin and rifampicin were evaluated in vitro as a possible new antibiotic combination against methicillin-resistant Staphylococcus aureus. An evaluation of 20 strains of methicillin-resistant Staph. aureus using microdilution checkerboard techniques at 10(5) cfu/ml showed neither synergy nor antagonism between novobiocin and rifampicin or between vancomycin and rifampicin. Agar surface inoculation of six strains of methicillin-resistant Staph. aureus showed increased synergy with increased inocula (10(6)-10(9) cfu) for novobiocin plus rifampicin compared to vancomycin plus rifampicin. Time-kill curves showed indifference at 6h for all combinations, whereas, at 24 and 48 h, they generally showed indifference, occasionally synergy, but never antagonism. The 'synergy' between novobiocin and rifampicin at higher inocula of methicillin-resistant Staph. aureus appears to be due to prevention of emergence of resistant organisms and may have clinical relevance. The combination of novobiocin-rifampicin merits further investigation.
对新生霉素和利福平进行了体外评估，以确定其作为一种可能的新型抗生素组合对抗耐甲氧西林金黄色葡萄球菌的效果。使用微量稀释棋盘法在10(5) cfu/ml浓度下对20株耐甲氧西林金黄色葡萄球菌进行评估，结果显示新生霉素与利福平之间或万古霉素与利福平之间既无协同作用也无拮抗作用。对6株耐甲氧西林金黄色葡萄球菌进行琼脂表面接种，结果显示与万古霉素加rifampicin相比，新生霉素加rifampicin随着接种量增加（10(6)-10(9) cfu）协同作用增强。时间-杀菌曲线显示所有组合在6小时时无差异，而在24和48小时时，它们通常无差异，偶尔有协同作用，但从未有拮抗作用。在耐甲氧西林金黄色葡萄球菌接种量较高时，新生霉素与利福平之间的“协同作用”似乎是由于防止耐药菌的出现，可能具有临床意义。新生霉素-利福平组合值得进一步研究。
